Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Latanoprost Versus Fotil

This study has been completed.
Information provided by:
Pharmaceutical Research Network Identifier:
First received: March 17, 2006
Last updated: October 23, 2007
Last verified: October 2007
To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.

Condition Intervention Phase
Open-Angle Glaucoma
Ocular Hypertension
Drug: latanoprost 0.005%
Drug: Fotil
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Pharmaceutical Research Network:

Estimated Enrollment: 36
Study Start Date: May 2005
Study Completion Date: October 2007

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adults with primary open-angle or pigment dispersion glaucoma, or ocular hypertension
  • untreated intraocular pressure should be between 24-36 mm Hg inclusive
  • visual acuity should be 5/50 or better in both eyes

Exclusion Criteria:

  • presence of exfoliation syndrome or exfoliation glaucoma
  • contraindications to study medications
  • any anticipated change in systemic hypotensive therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00304785

Gabinety Okulistyczne
Bydgoszcz, Poland, PL-85-670
Kierownik Kliniki Okulistycznej Akademii Medycznej
Poznan', Poland, PL-61-848
Instytut Jaskry
Warsaw, Poland, 00415
Katdra Klinika Okulityki Akademii Medycznej w Warszawie
Warsaw, Poland, 02-005
Ordynator Oddziału Okulistycznego Międzyleski Szpital Specjalistyczny
Warszawa, Poland, PL-04-749
Sponsors and Collaborators
Pharmaceutical Research Network
Study Director: William C. Stewart, MD Pharmaceutical Research Network, LLC
Principal Investigator: Józef Kałużny, Professor Gabinety Okulistyczne
Principal Investigator: Krystyna Pecold, Professor Kierownik Kliniki Okulistycznej Akademii Medycznej
Principal Investigator: Roman Sobecki, Dr. Ordynator Oddziału Okulistycznego Międzyleski Szpital Specjalistyczny
Principal Investigator: Krystyna Czechowisz-Janicka, Professor Instytut Jaskry
Principal Investigator: Dariusz Kecik, Professor Katdra Klinika Okulityki Akademii Medycznej w Warszawie
  More Information Identifier: NCT00304785     History of Changes
Other Study ID Numbers: PRN 03-026
Study First Received: March 17, 2006
Last Updated: October 23, 2007

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Antihypertensive Agents processed this record on April 27, 2017